List of Excipients in Branded Drug MODAFINIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	CELLULOSE, MICROCRYSTALLINE
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	CROSCARMELLOSE SODIUM
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	LACTOSE MONOHYDRATE
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	MAGNESIUM STEARATE
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	POVIDONE
STAT Rx USA LLC	MODAFINIL	modafinil	42549-678	STARCH, CORN
Aphena Pharma Solutions - Tennessee LLC	MODAFINIL	modafinil	43353-925	CELLULOSE, MICROCRYSTALLINE

Generic Drugs Containing MODAFINIL

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	modafinil	0378-5573	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Mylan Pharmaceuticals Inc	modafinil	0378-5573	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	modafinil	0378-5573	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	modafinil	0378-5573	LACTOSE MONOHYDRATE
Mylan Pharmaceuticals Inc	modafinil	0378-5573	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	modafinil	0378-5573	POVIDONE
Actavis Pharma Inc	modafinil	0591-3499	CROSCARMELLOSE SODIUM

What are the Most Frequently-Used Excipients in MODAFINIL?

# Of NDCs	Excipient
2	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS
20	CELLULOSE, MICROCRYSTALLINE
38	CROSCARMELLOSE SODIUM
17	CROSPOVIDONE
1	HYDROXYPROPYL CELLULOSE
44	LACTOSE MONOHYDRATE

Excipient Strategy and Commercial Opportunities for Modafinil

Last updated: March 2, 2026

What are the key excipient considerations for Modafinil?

Modafinil, a wakefulness-promoting agent, requires an excipient strategy that ensures stability, bioavailability, and patient acceptability. The formulation predominantly involves oral tablets. Critical excipient functions include disintegrants, binders, fillers, lubricants, and film-coating agents.

Common excipients in Modafinil formulations include:

• Lactose monohydrate: as a filler and binder.
• Microcrystalline cellulose: as a filler and disintegrant.
• Hydroxypropyl methylcellulose (HPMC): for controlled-release formulations.
• Magnesium stearate: as a lubricant.
• Opadry (film-coating systems): to improve stability and patient acceptance.

Formulation considerations:

• Stability: Excipients must avoid interactions that could compromise the drug's stability.
• Bioavailability: Excipients like disintegrants facilitate rapid dissolution.
• Patient acceptability: Coatings and flavorings improve compliance.

Major pharmaceutical companies traditionally utilize these excipients, but innovation focuses on controlled-release matrices and taste-masking agents.

How do excipient strategies impact commercial opportunities?

Market differentiation depends on formulation innovation. Specifically:

• Extended-release (ER) formulations: Use polymer matrices (HPMC, ethylcellulose) to prolong therapeutic effects, creating new patent opportunities and the ability to command premium prices.
• Taste-masked formulations: Improve patient adherence, especially in pediatric or sensitive patient groups.
• Reduced excipient loads: Minimize allergenic or regulatory hurdles, easing approval in different jurisdictions.

Manufacturers that develop proprietary excipient combinations or release mechanisms can extend patent life, reduce generic competition, and create a premium product segment.

Regulatory environment: Agencies prefer excipient ingredients with established safety profiles. Innovations, such as novel polymers, require rigorous safety data but can lead to market exclusivity through patents.

Supply chain considerations: Stable, high-quality excipient sources ensure manufacturing consistency, critical for scale-up and achieving regulatory compliance.

What are the patent implications for excipient innovations in Modafinil?

Patent strategies include:

• Patents on specific controlled-release matrices and processes.
• Patents on taste-masking techniques.
• Patents on novel excipient blends that improve stability or bioavailability.

Active patenting around excipients can extend monopoly periods post-oral drug patent expiration, offering competitive advantages.

What are commercial opportunities for excipient suppliers?

Procurement opportunities are driven by:

• Demand for high-purity, pharmaceutically approved excipients.
• Customization of formulations for ER or specific release profiles.
• Development of novel, patentable excipient systems.

Major excipient suppliers, such as DuPont, FMC, and Ashland, can capitalize on increasing demand for modified-release formulations and improved patient compliance.

Market dynamics and future trends

• Global Modafinil market size: Estimated at USD 1.4 billion in 2022, projected to grow at 4.8% CAGR through 2030.[1]
• Formulation innovations: Controlled-release and combination formulations are key drivers.
• Regulatory landscape: Stringent standards for excipient safety and usage clarity are maintained globally.

Emerging trends include:

• Development of natural excipients for cleaner labels.
• Use of 3D printing for personalized dosing.
• Integration of smart polymers for on-demand release.

Key Takeaways

• Excipient strategies for Modafinil concentrate on stability, bioavailability, and patient compliance.
• Controlled-release and taste-masking innovations serve as critical differentiation points.
• Patent protection around excipient formulations can extend market exclusivity.
• Suppliers of high-quality, innovative excipients are positioned to benefit from the growing market.
• Formulation advancements are aligned with market growth, regulatory trends, and demand for tailored therapies.

FAQs

Q1: What are the primary challenges in formulating Modafinil?
A1: Ensuring drug stability, rapid dissolution, and patient tolerability while integrating controlled-release mechanisms.

Q2: Can excipient innovation extend patent life for Modafinil products?
A2: Yes. Patent protections on novel excipient combinations and delivery systems can extend exclusivity beyond the initial drug patent.

Q3: How significant is the market for modified-release Modafinil formulations?
A3: It is increasingly important, driven by demand for sustained wakefulness and improved compliance, potentially commanding premium pricing.

Q4: Which excipients are most commonly used in Modafinil formulations?
A4: Lactose monohydrate, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, and film-coating agents.

Q5: How does regulatory scrutiny influence excipient choices?
A5: Preference is given to excipients with well-established safety profiles, though novel excipients require extensive safety documentation.

---

References

[1] MarketsandMarkets. (2022). Modafinil market size, share & trends.